Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

Yoshiaki Nakamura, M.D., Ph.D.; former Chief, International Research Promotion Office at National Cancer Center Hospital East

“These results show that ctDNA detection using a tissue-free assay was associated with a substantially increased risk of recurrence and melanoma-related death and often preceded clinical detection of disease.”

Yoshiaki Nakamura, M.D., Ph.D.; former Chief, International Research Promotion Office at National Cancer Center Hospital East

“Fast, broadly accessible testing would be valuable in helping to inform therapy for patients with substantially higher risk of melanoma recurrence and poorer survival than those who remained ctDNA-negative.”

Kenjiro Namikawa, M.D., Ph.D.; Chief, Department of Dermatologic Oncology at National Cancer Center Hospital

“Our findings suggest that serial ctDNA testing may provide a dynamic view of recurrence risk and potentially complement routine imaging, particularly in identifying patients at increased risk of distant relapse.”

Kenjiro Namikawa, M.D., Ph.D.; Chief, Department of Dermatologic Oncology at National Cancer Center Hospital

“Further studies will be important to determine whether and how ctDNA results could be incorporated into postoperative treatment and surveillance decisions.”

Helmy Eltoukhy, Chairman and co-CEO of Guardant Health

“The ability to identify patients at very high risk shortly after surgery, and to detect molecular recurrence before it appears clinically, could help inform more personalized surveillance and clinical trial strategies.”

Helmy Eltoukhy, Chairman and co-CEO of Guardant Health

“These findings also illustrate the advantages of a tissue-free approach that can deliver molecular insights without the logistical complexity of obtaining and analyzing a tumor specimen.”